Intuitive Surgical (NASDAQ: ISRG) reported fourth-quarter earnings and revenue that exceeded analyst expectations, supported by strong growth in both da Vinci and Ion procedures.
The robotic surgery company posted adjusted earnings per share of $2.53, well above the analyst consensus of $2.26. Revenue rose to $2.87 billion, exceeding expectations of $2.75 billion and increasing 19% from $2.41 billion in the same quarter last year.
Performance was driven by a 17% increase in da Vinci procedures and a 44% jump in Ion procedures during the quarter. Intuitive Surgical placed 532 da Vinci systems in the period, compared with 493 a year earlier, expanding its installed base to 11,106 systems, up 12% year over year.
Revenue from instruments and accessories increased 17% to $1.66 billion, while systems revenue climbed to $786 million from $655 million in the prior-year quarter.
Looking ahead, the company forecast worldwide da Vinci procedure growth of approximately 13% to 15% in 2026, down from 18% growth in 2025. Intuitive Surgical also projected a non-GAAP gross profit margin of 67% to 68% of revenue, including an estimated 1.2 percentage point impact from tariffs.
